APP and Alzheimer disease: Studies included in this review utilized a diverse array of AD models, such as 5XFAD, APP/PS1, APPSWE, and bilateral injection of amyloid-beta (Aβ) into the hippocampus, to evaluate the impact of meningeal lymphatic drainage enhancement therapies on disease outcomes.